Safety and Efficacy of SJP-0035 Ophthalmic Solution in Patients With Moderate to Severe Corneal Epithelial Disorders
Public ClinicalTrials.gov record NCT02929823. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Double-Masked, Randomized, Multicenter, Placebo-Controlled, Parallel-Group Study of SJP-0035 Ophthalmic Solution Compared With Placebo to Assess Safety and Efficacy of Two Dose Concentrations of SJP-0035 Ophthalmic Solution for Corneal Epithelial Wound Healing in Patients With Moderate to Severe Corneal Epithelial Disorders
Study identification
- NCT ID
- NCT02929823
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Senju Pharmaceutical Co., Ltd.
- Industry
- Enrollment
- 130 participants
Conditions and interventions
Conditions
Interventions
- High Dose SJP-0035 Ophthalmic Solution Drug
- Low Dose SJP-0035 Ophthalmic Solution Drug
- Vehicle of SJP-0035 Ophthalmic solution Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 2016
- Primary completion
- May 2, 2017
- Completion
- May 2, 2017
- Last update posted
- Apr 12, 2021
2016 – 2017
United States locations
- U.S. sites
- 19
- U.S. states
- 10
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Senju Investigational Site | Little Rock | Arkansas | 72205 | — |
| Senju Investigational Site | Glendora | California | 91741 | — |
| Senju Investigational Site | Lancaster | California | 93534 | — |
| Senju Investigational Site | Long Beach | California | 90805 | — |
| Senju Investigational Site | Montebello | California | 90640 | — |
| Senju Investigational Site | Pasadena | California | 91107 | — |
| Senju Investigational Site | Santa Ana | California | 92705 | — |
| Senju Investigational Site | Miami | Florida | 33143 | — |
| Senju Investigational Site | Hoffman Estates | Illinois | 60169 | — |
| Senju Investigational Site | Edgewood | Kentucky | 41017 | — |
| Senju Investigational Site | Louisville | Kentucky | 40206 | — |
| Senju Investigational Site | Kansas City | Missouri | 64111 | — |
| Senju Investigational Site | High Point | North Carolina | 27262 | — |
| Senju Investigational Site | Rapid City | South Dakota | 57701 | — |
| Senju Investigational Site | Cedar Park | Texas | 78613 | — |
| Senju Investigational Site | Houston | Texas | 77030 | — |
| Senju Investigational Site | Irving | Texas | 75039 | — |
| Senju Investigational Site | Falls Church | Virginia | 22044 | — |
| Senju Investigational Site | Norfolk | Virginia | 23502 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02929823, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 12, 2021 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02929823 live on ClinicalTrials.gov.